| Literature DB >> 26120055 |
L Miller1, D J Greensmith2, R Sankaranarayanan1, S C O'Neill1, D A Eisner1.
Abstract
2,5-Di-(tert-butyl)-1,4-benzohydroquinone (TBQ) is a reversible inhibitor of SERCA, potentially making it a useful tool to study the effects of SERCA inhibition in cardiac cells. However, it is unknown if TBQ also has effects on other components of ventricular Ca handling. The aim of these experiments was to characterise the effects of TBQ on Ca handling in rat ventricular myocytes and assess its suitability as a specific inhibitor of SERCA. This was achieved by voltage clamp via perforated patch and [Ca(2+)]i measurement using Fluo-3 AM. TBQ produced a fully reversible, concentration dependent decrease in the rate of systolic Ca decay. 10μM TBQ decreased the amplitude of the systolic Ca transient by 48±5% and the rate of decay by 54±6%. SR Ca content was also reduced by 62±4%. However, 10μM TBQ also decreased the peak L-type Ca current by 23±7%. At higher concentrations (100μM), TBQ also activated an outward current with a current-voltage relationship consistent with a potassium current. This outward current was abolished by Glibenclamide (100μM). These data show that TBQ can be used to reversibly inhibit SERCA. However, at concentrations that decrease SERCA activity, TBQ also decreases the L-type Ca current and (at higher concentrations) activates an outward current which appears to be an ATP dependent potassium current. We conclude that TBQ cannot be used as a specific inhibitor of SERCA in rat ventricular myocytes.Entities:
Keywords: Calcium; Myocyte; SERCA; TBQ
Mesh:
Substances:
Year: 2015 PMID: 26120055 PMCID: PMC4509554 DOI: 10.1016/j.ceca.2015.05.002
Source DB: PubMed Journal: Cell Calcium ISSN: 0143-4160 Impact factor: 6.817
Fig. 1The effects of TBQ on the Ca transient. (A) Specimen [Ca2+] transients measured with Fluo-3. The cell was stimulated at 0.5 Hz with a 100 ms duration depolarising pulse from −40 to 0 mV. TBQ was applied in the concentrations shown. (B) Expanded time base overlays showing averaged transients from (A). Left shows original records and right normalised. (C) Average data (n = 16 cells from 8 animals) showing (left) the amplitude of systolic Ca and (right) rate constant of decay of systolic Ca. All data have been normalised to the values before addition of TBQ (“C”). “W” denotes values after removing the final concentration of TBQ (*p < 0.05 vs. control).
Fig. 2The effect of TBQ on SR Ca content. (A) Specimen INCX records (top panel) and corresponding integrals (lower panel) in control (left) and following 10 μM TBQ (right) evoked by rapid application of 10 mM caffeine (white bar). (B) Average SR Ca (n = 5 cells from 3 animals, *p < 0.05 vs. control).
Fig. 3The effects of TBQ on sarcolemmal currents. (A) Specimen membrane currents in response to a 100 ms depolarising pulse from −40 to 0 mV. Panels show (left to right) control, increasing concentrations of TBQ and washout. (B) Average data (n = 17 cells from 8 animals) showing peak inward current (black). The effect on the rate constant of systolic calcium removal is superimposed for reference (grey and dashed curve). (C) ICa-LI–V plot in control (open symbols) and presence of 10 μM TBQ (filled symbols). (D) Average data shows the peak outward component of the currents represented by (A). (E) Specimen IV relationship produced by a voltage ramp protocol (−120 to 40 mV) showing the control current, the current after exposure to TBQ and the TBQ sensitive current determined by subtraction of TBQ from control (ITBQ). This record is typical of 5 experiments. *p < 0.05 vs. control.
Fig. 4Characterisation of sarcolemmal currents produced by TBQ. (A) Specimen current records. The cell was stimulated at 0.5 Hz with a 100 ms duration depolarising pulse from −40 to 0 mV. Currents were recorded in control then exposed to 100 μM TBQ. TBQ was then washed off and 100 μM Glibenclamide added before adding 100 μM TBQ with 100 μM Glibenclamide. (B) Average data (n = 4 cells from 3 animals) showing (left) the amplitude of the outward component and (right) the amplitude of the inward component. (C) Specimen IBa records in control and following 10 μM TBQ. (D) Average peak IBa data (n = 4 cells from 4 animals) (*p < 0.05 vs. control).
Fig. 5Does SERCA inhibition activate IK-ATP? (A) Specimen [Ca2+] transients showing original traces (left panel) and normalised traces (right panel) for direct comparison of the decay phase. 1 μM Thapsigargin was applied to inhibit SERCA. (B) Specimen ICa-L traces in control and following 1 μM Thapsigargin. Application of Thapsigargin was not associated with a decrease in ICa-L or activation of Io. Representative of 3 cells from 3 animals.